BUZZ-BioXcel jumps after mid-stage trial shows drug eases opioid withdrawal symptoms
Reuters03-05
BUZZ-BioXcel jumps after mid-stage trial shows drug eases opioid withdrawal symptoms
** Shares of drugmaker BioXcel TherapeuticsBTAI.O rise 23% to $2.03 premarket
** Co says its experimental drug, BXCL501, helped ease symptoms of opioid withdrawal by over 30% in a mid-stage study with 80 adults
** Adds that BXCL501 outperformed lofexidine, a non-opioid taken four times a day for withdrawal symptoms
** Also notes fewer side effects for BXCL501 vs. lofexidine, including lower rates of low blood pressure and no reported sedation
** BTAI fell ~73% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments